ESPAC-4: Combination versus single agent chemotherapy in resectable pancreatic cancer

Website Pancreatic Cancer UK

UK Clinical Trials, clinical research london

Phase III Trial
Why is this trial being carried out?
Previous trials have found that giving chemotherapy after surgical treatment for pancreatic cancer may help to prevent or delay the cancer coming back.

For patients who are fit enough following their surgery, gemcitabine chemotherapy may be offered as a standard treatment. Gemcitabine is a type of chemotherapy drug that is often used to treat advanced pancreatic cancer but in this situation it is being used to reduce the risk of the cancer returning after surgical removal.

This trial is looking at whether adding an additional chemotherapy drug, capecitabine, to gemcitabine chemotherapy treatment can improve the effectiveness of chemotherapy treatment. The trial will also look at the side effects of this combined treatment.

Who is the trial suitable for?
This trial is suitable for patients who have had surgery to remove pancreatic or ampullary cancer within the last 12 weeks where the surgeon was able to remove the cancer completely. Patients also need to have recovered well from the surgery. Your doctor(s) will explain these any other requirements to join the trial.

Trial centres
The trial is open at 80 locations nationwide. For more information on locations follow the CancerHelp UK link below.

Recruitment start date: October 2008

Recruitment end date: October 2017

Pancreatic Cancer UK
2nd Floor, Camelford House
89 Albert Embankment
London
SE1 7TW